IAAG
NBIX icon

Innovative Asset Advisors Group’s Neurocrine Biosciences NBIX Stock Holding History

Innovative Asset Advisors Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19
Closed -$2.5K – 748
2026
Q1 		$2.5K Buy
+19
New +$2.52K ﹤0.01% 872

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Innovative Asset Advisors Group's NBIX Position: Q2 2026 in Review

Innovative Asset Advisors Group sold out of Neurocrine Biosciences (NBIX) in Q2 2026, closing a stake of 19 shares — an estimated $2.5K sold.

Innovative Asset Advisors Group first reported a position in NBIX in Q1 2026 and held it in 1 quarter. The position peaked at $2.5K in Q1 2026. 733 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Innovative Asset Advisors Group reported no remaining Neurocrine Biosciences position as of Q2 2026 after selling out during the quarter.
  • Innovative Asset Advisors Group sold 19 Neurocrine Biosciences shares in Q2 2026, an estimated $2.5K.
  • Innovative Asset Advisors Group first reported a position in Neurocrine Biosciences in Q1 2026 and held it in 1 quarter.
  • Innovative Asset Advisors Group's Neurocrine Biosciences position peaked at $2.5K in Q1 2026.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Innovative Asset Advisors Group's 13F filing for Q2 2026, filed 5 Aug 2026.